144 related articles for article (PubMed ID: 9836448)
1. Inhibition of topoisomerases by antitumor prostaglandins.
Suzuki K; Shono F; Uyeda M
Biosci Biotechnol Biochem; 1998 Oct; 62(10):2073-5. PubMed ID: 9836448
[TBL] [Abstract][Full Text] [Related]
2. Inhibitory properties of antitumor prostaglandins against topoisomerases.
Suzuki K; Uyeda M
Biosci Biotechnol Biochem; 2002 Aug; 66(8):1706-12. PubMed ID: 12353631
[TBL] [Abstract][Full Text] [Related]
3. Prostaglandins in the treatment of cancer.
Sasaki H; Fukushima M
Anticancer Drugs; 1994 Apr; 5(2):131-8. PubMed ID: 8049495
[TBL] [Abstract][Full Text] [Related]
4. Modulation of human lymphocyte response to phytohemagglutinin by antineoplastic prostaglandins.
Kikuchi Y; Kita T; Hirata J; Kuki E; Nagata I; Fukushima M
Int J Immunopharmacol; 1992 Jan; 14(1):105-10. PubMed ID: 1582730
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of the proliferation of transformed epidermal cells in culture by various prostaglandins.
Ikai K; Ujihara M; Kashihara M; Fukushima M
J Invest Dermatol; 1987 Jul; 89(1):69-72. PubMed ID: 2439606
[TBL] [Abstract][Full Text] [Related]
6. Stereoselective conjugation of prostaglandin A2 and prostaglandin J2 with glutathione, catalyzed by the human glutathione S-transferases A1-1, A2-2, M1a-1a, and P1-1.
Bogaards JJ; Venekamp JC; van Bladeren PJ
Chem Res Toxicol; 1997 Mar; 10(3):310-7. PubMed ID: 9084911
[TBL] [Abstract][Full Text] [Related]
7. Inhibitory activities of (-)-epigallocatechin-3-O-gallate against topoisomerases I and II.
Suzuki K; Yahara S; Hashimoto F; Uyeda M
Biol Pharm Bull; 2001 Sep; 24(9):1088-90. PubMed ID: 11558576
[TBL] [Abstract][Full Text] [Related]
8. New insight for fluoroquinophenoxazine derivatives as possibly new potent topoisomerase I inhibitor.
Kang DH; Kim JS; Jung MJ; Lee ES; Jahng Y; Kwon Y; Na Y
Bioorg Med Chem Lett; 2008 Feb; 18(4):1520-4. PubMed ID: 18178085
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant effects of antineoplastic prostaglandins to cisplatin in nude mice bearing human ovarian cancer cells.
Kikuchi Y; Kita T; Miyauchi M; Hirata J; Sasa H; Nagata I; Fukushima M
J Cancer Res Clin Oncol; 1992; 118(6):453-7. PubMed ID: 1618893
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of DNA topoisomerases by nidulalin A derivatives.
Sato S; Fukuda Y; Nakagawa R; Tsuji T; Umemura K; Andoh T
Biol Pharm Bull; 2000 Apr; 23(4):511-2. PubMed ID: 10784438
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity of delta 7-prostaglandin A1 and delta 12-prostaglandin J2 in vitro and in vivo.
Kato T; Fukushima M; Kurozumi S; Noyori R
Cancer Res; 1986 Jul; 46(7):3538-42. PubMed ID: 3708585
[TBL] [Abstract][Full Text] [Related]
12. Synthesis of 2-(thienyl-2-yl or -3-yl)-4-furyl-6-aryl pyridine derivatives and evaluation of their topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship.
Thapa P; Karki R; Choi H; Choi JH; Yun M; Jeong BS; Jung MJ; Nam JM; Na Y; Cho WJ; Kwon Y; Lee ES
Bioorg Med Chem; 2010 Mar; 18(6):2245-2254. PubMed ID: 20188578
[TBL] [Abstract][Full Text] [Related]
13. Topostatin, a novel inhibitor of topoisomerases I and II produced by Thermomonospora alba strain No. 1520. I. Taxonomy, fermentation, isolation and biological activities.
Suzuki K; Nagao K; Monnai Y; Yagi A; Uyeda M
J Antibiot (Tokyo); 1998 Nov; 51(11):991-8. PubMed ID: 9918391
[TBL] [Abstract][Full Text] [Related]
14. Topoisomerase enzymes as drug targets.
Guichard SM; Danks MK
Curr Opin Oncol; 1999 Nov; 11(6):482-9. PubMed ID: 10550012
[TBL] [Abstract][Full Text] [Related]
15. Vitamin E succinate potentiates the inhibitory effect of prostaglandins on oral squamous carcinoma cell proliferation.
elAttar TM; Lin HS
Prostaglandins Leukot Essent Fatty Acids; 1995 Jan; 52(1):69-73. PubMed ID: 7708823
[TBL] [Abstract][Full Text] [Related]
16. BN 80927: a novel homocamptothecin with inhibitory activities on both topoisomerase I and topoisomerase II.
Lavergne O; Harnett J; Rolland A; Lanco C; Lesueur-Ginot L; Demarquay D; Huchet M; Coulomb H; Bigg DC
Bioorg Med Chem Lett; 1999 Sep; 9(17):2599-602. PubMed ID: 10498216
[TBL] [Abstract][Full Text] [Related]
17. Preferential binding of growth inhibitory prostaglandins by the target protein of a carcinogen.
Khan SH; Sorof S
Proc Natl Acad Sci U S A; 1990 Dec; 87(23):9401-5. PubMed ID: 2251282
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of growth in oral squamous carcinoma cells by cyclopentenone prostaglandins: comparison with chemotherapeutic agents.
ElAttar TM; Virji AS
Prostaglandins Leukot Essent Fatty Acids; 1997 Jun; 56(6):461-5. PubMed ID: 9223658
[TBL] [Abstract][Full Text] [Related]
19. Mechanism of cytotoxicity of N-[2-(dimethylamino)ethyl] acridine-4-carboxamide and of its 7-chloro derivative: the roles of topoisomerases I and II.
Bridewell DJ; Finlay GJ; Baguley BC
Cancer Chemother Pharmacol; 1999; 43(4):302-8. PubMed ID: 10071981
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of topoisomerases by fatty acids.
Suzuki K; Shono F; Kai H; Uno T; Uyeda M
J Enzyme Inhib; 2000; 15(4):357-66. PubMed ID: 10995067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
